Valuation: TG Therapeutics, Inc.

Market Cap 7.78B 6.8B 6.28B 5.79B 10.91B 750B 11.15B 75.04B 29.51B 367B 29.24B 28.59B 1,264B P/E 2026 *
41.3x
P/E 2027 * 19x
Enterprise Value 7.81B 6.83B 6.3B 5.81B 10.94B 752B 11.18B 75.28B 29.61B 368B 29.33B 28.69B 1,268B EV / Sales 2026 *
8.29x
EV / Sales 2027 * 5.71x
Free-Float
88.55%
Yield 2026 *
-
Yield 2027 * -
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating MT
07-06 TG Therapeutics Initiates Phase 2 Trial Evaluating BRIUMVI In Patients With Treatment-Resistant Schizophrenia CI
07-06 TG Therapeutics Begins Phase 2 Trial of Briumvi in Treatment-Resistant Schizophrenia MT
06-09 TG Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02:00 PM
06-09 TG Therapeutics Reports Positive Topline Phase 1 Data For Subcutaneous BRIUMVI In Patients With Myasthenia Gravis and Initiates Potential Registration Directed Randomized Phase 2 Trial CI
06-09 TG Therapeutics Begins Phase 2 Myasthenia Gravis Trial MT
06-03 TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy MT
06-03 TG Therapeutics, Inc. Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous BRIUMVI CI
06-01 TG Therapeutics announces publication of post-hoc data from the phase 3 Ultimate I & II trials in treatment naive patients with relapsing forms of MS published in Frontiers in Immunology RE
06-01 TG Therapeutics, Inc. Publishes Post-Hoc Data from Phase 3 Ultimate I and Ii Trials Evaluating Briumvi in Treatment-Naïve Patients with Relapsing Multiple Sclerosis CI
05-27 Tg Therapeutics Announces Positive Topline Results from Phase 3 Enhance Trial CI
05-27 TG Therapeutics Says Phase 3 Briumvi Trial Met Main Goal MT
1 day-0.02%
1 week-4.11%
Current month-0.31%
1 month+6.35%
3 months+55.02%
6 months+77.02%
Current year+83.73%
1 week 53.35
Extreme 53.35
56.92
1 month 51.15
Extreme 51.15
59.3
Current year 26.76
Extreme 26.76
59.3
1 year 25.28
Extreme 25.28
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 28/12/2011
Director of Finance/CFO 44 28/12/2011
Investor Relations Contact - 30/11/2011
Director TitleAgeSince
Chairman 60 28/12/2011
Director/Board Member 79 29/02/2012
Director/Board Member 62 08/11/2012
Date Insider Type Main position Quantity % Market Cap.
11/06/26 Free

Director

8,325 0.0054%
11/06/26 Free

Director

8,325 0.0054%
11/06/26 Free

Director

8,325 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%-4.11%+39.76%+154.98% 7.78B
+0.31%-1.19%+54.23%+162.66% 1,043B
+1.23%-1.54%+55.25%+59.06% 602B
+0.45%+3.25%+33.82%+89.97% 449B
+0.78%-0.71%+30.04%+24.61% 327B
+1.41%+0.58%+33.92%+47.20% 279B
-0.27%-1.87%+22.13%+23.47% 264B
-2.37%-0.22%+21.57%+59.14% 201B
-0.93%+3.95%+24.04%+74.19% 169B
-0.30%+3.58%+1.85%-30.19% 143B
Average -0.01%-1.32%+31.66%+66.51% 348.48B
Weighted average by Cap. +0.32%-1.83%+39.91%+84.45%

Financials

2026 *2027 *
Net sales 942M 823M 760M 700M 1.32B 90.74B 1.35B 9.08B 3.57B 44.44B 3.54B 3.46B 153B 1.27B 1.11B 1.02B 942M 1.78B 122B 1.82B 12.22B 4.81B 59.79B 4.76B 4.66B 206B
Net income 207M 181M 167M 154M 290M 19.93B 296M 2B 785M 9.76B 777M 760M 33.61B 483M 422M 389M 359M 676M 46.49B 691M 4.65B 1.83B 22.77B 1.81B 1.77B 78.39B
Net Debt 25.33M 22.13M 20.42M 18.83M 35.48M 2.44B 36.27M 244M 96.01M 1.19B 95.11M 93.03M 4.11B -541M -473M -436M -402M -758M -52.09B -775M -5.21B -2.05B -25.51B -2.03B -1.99B -87.82B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
17/07/26 US$54.87 -0.11% 3,408,012
16/07/26 US$54.93 -2.62% 2,191,880
15/07/26 US$56.41 +2.77% 1,615,953
14/07/26 US$54.89 -0.22% 2,029,897
13/07/26 US$55.01 -3.69% 1,950,898
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
54.93USD
Average target price
58.38USD
Spread / Average Target
+6.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock